Literature DB >> 29335927

miRNAs as Potential Treatment Targets and Treatment Options in Cancer.

Nina Petrovic1,2, Sercan Ergun3,4.   

Abstract

Standard cancer therapies for solid malignancies, such as chemotherapy and radiotherapy, are not target specific against cancer cells and are often not fully efficacious. Chemotherapy and radiotherapy may cause side effects, and the need to develop additional strategies for cancer treatment is urgent. MicroRNAs (miRNAs) are small non-coding RNAs with heterogeneous functions and have been described in almost every known cancer model. Besides their basic tumor-suppressive and oncogenic functions, they also have the potential to modulate chemotherapy and radiotherapy and to be manipulated with chemical compounds to make them chemically suitable for efficient delivery to cancer cells. It has been suggested that the level of expression of specific miRNAs could increase treatment efficacy by determining the stage of chemotherapy/radiotherapy sensitivity. Application of miRNAs alone or in combination with standard therapeutic strategies may significantly improve the success of cancer treatments in the future.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29335927     DOI: 10.1007/s40291-017-0314-8

Source DB:  PubMed          Journal:  Mol Diagn Ther        ISSN: 1177-1062            Impact factor:   4.074


  68 in total

Review 1.  Small molecule compounds targeting miRNAs for cancer therapy.

Authors:  Paloma Del C Monroig; Lu Chen; Shuxing Zhang; George A Calin
Journal:  Adv Drug Deliv Rev       Date:  2014-09-17       Impact factor: 15.470

2.  Changes in miR-221/222 Levels in Invasive and In Situ Carcinomas of the Breast: Differences in Association with Estrogen Receptor and TIMP3 Expression Levels.

Authors:  Nina Petrovic; Radoslav Davidovic; Snezana Jovanovic-Cupic; Milena Krajnovic; Silvana Lukic; Milan Petrovic; Jelena Roganovic
Journal:  Mol Diagn Ther       Date:  2016-12       Impact factor: 4.074

3.  Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators.

Authors:  Marta Geretto; Alessandra Pulliero; Camillo Rosano; Dinara Zhabayeva; Rakhmet Bersimbaev; Alberto Izzotti
Journal:  Am J Cancer Res       Date:  2017-06-01       Impact factor: 6.166

4.  MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma.

Authors:  Ahmed Fawzy Ibrahim; Ulrike Weirauch; Maren Thomas; Arnold Grünweller; Roland K Hartmann; Achim Aigner
Journal:  Cancer Res       Date:  2011-06-20       Impact factor: 12.701

5.  MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF.

Authors:  Neda Mosakhani; Leo Lahti; Ioana Borze; Marja-Liisa Karjalainen-Lindsberg; Jari Sundström; Raija Ristamäki; Pia Osterlund; Sakari Knuutila; Virinder Kaur Sarhadi
Journal:  Cancer Genet       Date:  2012-10-23

6.  Circulating microRNA-451 as a predictor of resistance to neoadjuvant chemotherapy in breast cancer.

Authors:  Xi Gu; Jin-Qi Xue; Si-Jia Han; Song-Ying Qian; Wen-Hai Zhang
Journal:  Cancer Biomark       Date:  2016       Impact factor: 4.388

Review 7.  MicroRNA: potential targets for the development of novel drugs?

Authors:  Wei Wu
Journal:  Drugs R D       Date:  2010

Review 8.  MicroRNAs as Biomarkers for Liver Disease and Hepatocellular Carcinoma.

Authors:  C Nelson Hayes; Kazuaki Chayama
Journal:  Int J Mol Sci       Date:  2016-02-24       Impact factor: 5.923

9.  Formulation of Anti-miR-21 and 4-Hydroxytamoxifen Co-loaded Biodegradable Polymer Nanoparticles and Their Antiproliferative Effect on Breast Cancer Cells.

Authors:  Rammohan Devulapally; Thillai V Sekar; Ramasamy Paulmurugan
Journal:  Mol Pharm       Date:  2015-04-28       Impact factor: 4.939

10.  The anti-miR21 antagomir, a therapeutic tool for colorectal cancer, has a potential synergistic effect by perturbing an angiogenesis-associated miR30.

Authors:  Min-Sun Song; John J Rossi
Journal:  Front Genet       Date:  2014-01-02       Impact factor: 4.599

View more
  15 in total

Review 1.  Epigenetic regulation in cardiovascular disease: mechanisms and advances in clinical trials.

Authors:  Yuncong Shi; Huanji Zhang; Suli Huang; Li Yin; Feng Wang; Pei Luo; Hui Huang
Journal:  Signal Transduct Target Ther       Date:  2022-06-25

Review 2.  Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge.

Authors:  Milica Nedeljković; Ana Damjanović
Journal:  Cells       Date:  2019-08-22       Impact factor: 6.600

3.  STAT3 Regulates miR-384 Transcription During Th17 Polarization.

Authors:  Jingjing Han; Yaping Liu; Fei Zhen; Wen Yuan; Wei Zhang; Xiaotao Song; Fuxing Dong; Ruiqin Yao; Xuebin Qu
Journal:  Front Cell Dev Biol       Date:  2019-11-01

4.  MicroRNA-497-5p Induces Cell Cycle Arrest Of Cervical Cancer Cells In S Phase By Targeting CBX4.

Authors:  Yani Chen; Juan Du; Yu Wang; Haiyan Shi; Qiuyu Jiang; Yangfeng Wang; Huahua Zhang; Yameng Wei; Wanjuan Xue; Zhiying Pu; Yi Gao; Dan Li; Yun Feng; Jing Yan; Jing Zhang
Journal:  Onco Targets Ther       Date:  2019-12-02       Impact factor: 4.147

Review 5.  miRNAs as biomarkers for early cancer detection and their application in the development of new diagnostic tools.

Authors:  Leonardo J Galvão-Lima; Antonio H F Morais; Ricardo A M Valentim; Elio J S S Barreto
Journal:  Biomed Eng Online       Date:  2021-02-16       Impact factor: 2.819

Review 6.  Breast Cancer Response to Therapy: Can microRNAs Lead the Way?

Authors:  Nina Petrović; Irina Nakashidze; Milica Nedeljković
Journal:  J Mammary Gland Biol Neoplasia       Date:  2021-01-21       Impact factor: 2.673

7.  Cytotoxic activities of Hypericum perforatum L. extracts against 2D and 3D cancer cell models.

Authors:  Ivana Z Matić; Sercan Ergün; Marija Đorđić Crnogorac; Sema Misir; Yüksel Aliyazicioğlu; Ana Damjanović; Hurija Džudžević-Čančar; Tatjana Stanojković; Kalbiye Konanç; Nina Petrović
Journal:  Cytotechnology       Date:  2021-04-01       Impact factor: 2.040

Review 8.  The Multiple Roles of Hepatitis B Virus X Protein (HBx) Dysregulated MicroRNA in Hepatitis B Virus-Associated Hepatocellular Carcinoma (HBV-HCC) and Immune Pathways.

Authors:  Kurt Sartorius; Leo Swadling; Ping An; Julia Makarova; Cheryl Winkler; Anil Chuturgoon; Anna Kramvis
Journal:  Viruses       Date:  2020-07-10       Impact factor: 5.818

9.  MicroRNA-421-targeted PDCD4 regulates breast cancer cell proliferation.

Authors:  Yiwei Wang; Zipeng Liu; Jian Shen
Journal:  Int J Mol Med       Date:  2018-10-15       Impact factor: 4.101

10.  miR-744-5p Inhibits Non-Small Cell Lung Cancer Proliferation and Invasion by Directly Targeting PAX2.

Authors:  Shaolin Chen; Fei Shi; Weixing Zhang; Yuqi Zhou; Jing Huang
Journal:  Technol Cancer Res Treat       Date:  2019-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.